Therapy for Cancer
The conventional treatment for cancer is a balancing act. Patients are given as much chemotherapy as their body can tolerate. It is like killing flies with a cannonball instead of fly swatter. You get rid of some flies, yes, but you have a lot of collateral damage. Good cells die along with the bad. Over time (and sometimes a fairly short period of time, days rather than weeks), this massive bombardment can lead to poor blood counts, organ failure, and death. Because the already poorly functioning immune system is subjected to radiation and toxic drugs, it is difficult to deliver a “cure.”
A time-tested, modified form of chemotherapy has been used successfully and safely around the world for more than 70 years. It is called IPTLD, or Insulin Potentiation Targeted Low Dose therapy.
IPTLD uses about one-tenth the dosage of a conventional chemotherapy regime, and no radiation. IPTLD provides a safer, much gentler alternative to conventional chemotherapy, without the harsh side effects. When combined with complementary therapies to nurture the body, it is also more effective. It is a smart way to approach cancer based on what makes cancer cells vulnerable.
Now, what would happen if, in addition to glucose, you add a little bit of chemotherapy to the mixture? Bingo again – the chemotherapy drugs are taken up into the cancer cells. The healthy cells are not bombarded. This is why patients undergoing IPT do not experience the severe side effects of conventional therapy. Generally, IPT patients do not go bald, nor do they experience severe nausea or organ damage, and seldom do they drop their white blood cell counts.
The word "potentiate" means to make stronger or more effective. In this case, it means that insulin makes the chemotherapy more effective. A 1981 study conducted at George Washington University showed that when the chemotherapy drug, methotrexate, is combined with insulin, the drug's cell-killing effect increased by a factor of 10,000. Because insulin enhances the effectiveness of the drugs, IPT uses only 10% - 15% of standard dose of drugs. There is no need to overwhelm a patient with large quantities of drugs in the hope that the drugs will kill the cancer before they kill the patient’s immune system.
There is a second way that insulin helps us defeat cancer. Insulin stimulates cells to grow, which they do by dividing. Cancer cells are most vulnerable to many chemotherapeutic agents when they are dividing. With IPT, we use insulin’s stimulating properties to catch more cancer cells in the process of dividing, so more of the drugs are absorbed than if division had not been encouraged.
Scavo LM, Karas et al. Insulin-Like Growth Factor-I Stimulates Both Cell Growth and Lipogenesis during Differentiation of Human Mesenchymal Stem Cells into Adipocytes. J Clin Endocrin Metab 89;7:3542-3552.